Integrated BioPharma — Q3 2026 Earnings Summary

Financial Performance:

• Total revenue for the quarter ended September 30, 2026, was $9.9 million, a decrease of $2.8 million (approximately 22.0%) compared to $12.7 million in the same period in 2025.
• Gross profit turned negative to $(112) thousand in 2026, compared to a gross profit of $1.019 million in 2025.
• Operating loss was $1.0 million (specifically $(961) thousand) in 2026, reversing an operating income of $0.2 million (specifically $163 thousand) in 2025.
• Net loss was approximately $0.7 million (specifically $(691) thousand) in 2026, compared to net income of approximately $0.1 million (specifically $123 thousand) in 2025.
• Diluted net loss per share was $(0.02) in 2026, compared to $0.00 per share in 2025.
• Cost of sales was $10.025 million in 2026 versus $11.670 million in 2025.
• Selling and administrative expenses were $849 thousand in 2026, slightly down from $856 thousand in 2025.
• Other income, net, increased to $38 thousand in 2026 from $33 thousand in 2025.
• Income tax benefit was $232 thousand in 2026, compared to an expense of $73 thousand in 2025.

Business Segments and Product Lines:

• The Contract Manufacturing Segment relies heavily on two largest customers, which represented approximately 88% of total revenue in Q3 2026 and 87% in Q3 2025.

Management Commentary and Tone:

• Co-Chief Executive Officers Riva Sheppard and Christina Kay acknowledged the 22% revenue decrease and highlighted the high concentration of revenue from the two largest customers in the Contract Manufacturing Segment.

Other Key Points:

• The company is engaged in the manufacturing, distribution, marketing, and sales of vitamins, nutritional supplements, and herbal products.
• The press release includes a standard disclaimer regarding forward-looking statements and risks such as loss of market share, competition, regulatory changes, and customer concentration.